ClinicalTrials.gg
RecruitingNCT06399640Updated Aug 19, 2026

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

A Phase 1 interventional study of Eltanexor and Venetoclax in Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia, sponsored by Vanderbilt-Ingram Cancer Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Vanderbilt-Ingram Cancer Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,363 studies in Myelodysplastic Syndromes with a site in United States — 172 open to participants now, 278 under way, 17 of them phase 3. Myelodysplastic Syndromes · United States.

Planned enrollment
368th of 1,189
60 · median 35
Started
2024
with 36 others
Phase 1
384 of 1,363
55 open now
Primary completion
2027-02
later than 99 of 274 live
Registered
1,281st of 1,363
by date

Among the 1,363 studies in Myelodysplastic Syndromes with a site in United States, this one is the 368th largest by planned enrollment of the 1,189 interventional ones that give a count, is one of 37 that started in 2024, is one of 384 in phase 1, reaches primary completion later than 99 of the 274 other live ones, and was the 1,281st registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 319 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

172 of the 1,363 studies in Myelodysplastic Syndromes with a site in United States are open now. Recruiting first, the newest first:

167 more — sign in →

All 172 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 260 Myelodysplastic Syndromes studies recruiting now, 165 (63%) set no upper age limit and 68 (26%) stop at 75 or younger; 56 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,363 studies in Myelodysplastic Syndromes with a site in United States, or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Eltanexor works by trapping "tumor suppressing proteins" within the cell, thus causing the cancer cells to die or stop growing. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving eltanexor together with venetoclax may be safe, tolerable and/or effective in treating patients with relapsed or refractory MDS or AML.

Read the detailed description

Primary objective:

  • To establish the safe and biologically effective dose (BED) of eltanexor in combination with venetoclax in patients with R/R MDS and/or AML

Secondary objectives:

  • To estimate the complete remission (CR) rate with eltanexor and venetoclax in patients with R/R MDS and/or AML
  • To assess the overall response rate (ORR) following treatment with eltanexor/venetoclax
  • To assess the overall survival of patients
  • To assess the progression free survival (PFS) and duration of response (DOR) in patients treated with eltanexor/venetoclax

Exploratory objectives:

  • To assess differential response between MDS and AML cohorts
  • To develop and evaluate a phenotypic flow-based assay to predict response to eltanexor/venetoclax
  • To assess the effect of mutational changes on response to eltanexor/venetoclax
  • To measure the rates of measurable residual disease with eltanexor/venetoclax

OUTLINE: This is a dose-escalation study of eltanexor in combination with venetoclax.

Patients receive eltanexor orally (PO) once per day (QD) for 5 days per week for 14, 21, or 28 days every cycle, and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for up to 24 months.

03

Conditions studied

  • Relapsed Myelodysplastic Syndrome
  • Refractory Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Age >/= 18 years at the time of signing the Form (ICF); must voluntarily sign an ICF; and must be able to meet all study requirements.

For Myelodysplastic Syndrome (MDS):

Morphologically confirmed diagnosis of MDS with increased blasts (>/= 5%), with a prior DNA methyltransferase inhibitor (DNMTi) treatment and progression after 2 cycles or stable disease after 4 cycles

For Acute Myeloid Leukemia (AML):

Morphologically confirmed diagnosis of AML in accordance with WHO diagnostic criteria that is following >/= 1 line(s) of therapy.

  • WBC must be less than 25,000/ul prior to study start (hydroxyurea allowed).
  • A bone marrow aspirate must be performed, and tissue collected for entrance to the trial unless circulating blasts >/= 5% in which case, peripheral blood can be used.
  • Performance Status of 0 - 2.
  • Must have adequate hepatic and renal function as demonstrated by the following:

(SGPT) and/or AST (SGOT) \</= 3x (ULN); Total \</= 1.5x ULN; Calculated > 50 ml/min (per the Cockroft-Gault formula).

- Willingness to abide by all study requirements, including , maintenance of a pill diary, and acceptance of recommended supportive care medications.

Exclusion criteria

Exclusion Criteria:

  • Anticancer therapy, including agents \</= 2 weeks or \</= 5 half-lives of the drug, whichever is shorter, prior to C1D1. (Use of hydroxyurea is permitted).
  • Inadequate recovery from toxicity attributed to prior anti-cancer therapy to \</= Grade 1 ( v5.0), excluding alopecia or fatigue.
  • Prior treatment with SINE compounds or other inhibitors of XPO1.
  • History of hematopoietic stem cell transplant (HCT), or other cellular therapy product, within 3 months.
  • Active acute or chronic requiring calcineurin inhibitors or dosing >/= 10mg/day or patients within 4 weeks of stopping calcineurin inhibitors for GVHD.
  • Radiation therapy or major surgery within 3 weeks.
  • Active, uncontrolled infection. Patients with infection under active treatment and controlled with antibiotics are eligible. Prophylaxis, even if parenteral, is acceptable.
  • Inability to swallow oral medications.
  • Active documented central nervous system leukemia.
  • Second active within past 2 years except for basal or squamous cell carcinoma of the skin, ductal carcinoma of breast in situ or cervical carcinoma in situ.
  • Women of childbearing age or potential must have negative pregnancy test and must not be actively breastfeeding to enroll on the study
  • cardiovascular disease with major event or cardiac intervention within the past 6 months (e.g. percutaneous intervention, coronary artery bypass graft, documented cardiac heart failure) as determined by the investigator.
  • corrected by Fridericia's formula (QTcF)>470msec for both males and females on screening . Patients with a bundle branch block or in-situ pacemaker must have appropriate QT interval corrections for these conditions.
  • Any condition not listed but deemed by the investigator to make the patient a poor candidate for clinical trial and/or treatment with investigational agents.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Eltanexor + Venetoclax

    Participants receive eltanexor PO QD for 5 days per week for 14, 21, or 28 days every cycle, and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants undergo bone marrow aspiration and biopsy and blood sample collection throughout the study.

    Drug: Eltanexor · Drug: Venetoclax · Procedure: Bone Marrow Aspiration and Biopsy · Procedure: Biospecimen Collection

Interventions

  • Eltanexor will be taken by mouth

    Also known as: KPT-8602

  • Venetoclax will be taken by mouth

  • ProcedureBone Marrow Aspiration and Biopsy

    Undergo bone marrow aspiration and biopsy

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Adverse medical events will be tabulated and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.

    Time frame: Up to 2 years

  2. Biologically effective dose (BED) of eltanexor in combination with venetoclax

    Measured by complete remission

    Time frame: Up to 2 years

Secondary outcomes

  1. Complete remission

    By 95% (e.g. based on standard Gaussian methods or bootstrap methods, as appropriate) confidence intervals.

    Time frame: Up to 2 years

  2. Overall response rate

    By 95% (e.g. based on standard Gaussian methods or bootstrap methods, as appropriate) confidence intervals.

    Time frame: Up to 2 years

  3. Progression free survival

    Will be estimated using the method of Kaplan and Meier accompanied by 95% (e.g. based on standard Gaussian methods or bootstrap methods, as appropriate) confidence intervals.

    Time frame: Up to 2 years

  4. Overall survival

    Will be estimated using the method of Kaplan and Meier accompanied by 95% (e.g. based on standard Gaussian methods or bootstrap methods, as appropriate) confidence intervals.

    Time frame: From date on study to death for any reason, up to 2 years

  5. Duration of response

    Will be estimated using the method of Kaplan and Meier accompanied by 95% (e.g. based on standard Gaussian methods or bootstrap methods, as appropriate) confidence intervals.

    Time frame: From the date of first objective response until disease progression or death for any reason up to 2 years

07

Study locations

2 of 2 sites recruiting
  • Baptist Health Care Corporation
    Memphis, Tennessee 38138, United States
    Recruiting
  • Vanderbilt University/Ingram Cancer Center
    Nashville, Tennessee 37203, United States
    Recruiting
    • Vanderbilt-Ingram Service Services for Timely Access · Contactcip@vumc.org · 800-811-8480
    • Somedeb Ball, MD · Principal investigator
08

References and documents

Publications

  • Ball S, Awan FT, Tomlinson BK, Stopczynski T, Fischer MA, Zhao Z, Fedorov K, Kishtagari A, Mohan SR, Ayers GD, Byrne MT, Savona MR. Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol. 2026 May;101(5):1019-1024. doi: 10.1002/ajh.70266. Epub 2026 Mar 8. PubMed 41796974 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Feb 2027, 29 months after the start.

Of 136 non-industry phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 92. This study's planned 29 months is below that.

Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 6, 2024
StartActual
Aug 14, 2024
Primary completionEst.
Feb 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06399640
Responsible party
Somedeb Ball (Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center) — Principal investigator
First posted
May 6, 2024
Start date
Aug 14, 2024
Primary completion
Feb 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Vanderbilt-Ingram Services for Timely Access
Contact
cip@vumc.org
800-811-8480
Somedeb Ball, MD
principal investigator · Vanderbilt University/Ingram Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltanexor

Start the discussion